United States Radioimmunoassay Market Report by Product, Application, End User, States and Company Analysis, 2026-2034
Buy NowUnited States Radioimmunoassay Market Size and Forecast
United States Radioimmunoassay Market is projected to grow from US$ 290.64 million in 2025 to US$ 422.71 million by 2034, registering a compound annual growth rate (CAGR) of 4.25% during 2026–2034. Market growth is driven by increasing demand for sensitive diagnostic testing, rising prevalence of chronic and endocrine disorders, and expanding applications in clinical research and biotechnology. Additionally, continued advancements in laboratory technologies, growing research investments, and demand for accurate hormone and biomarker analysis are expected to support market expansion across the United States.
What Is the Radioimmunoassay Market and What Are Its Uses and Popularity in the USA?
The United States Radioimmunoassay (RIA) Market comprises diagnostic kits, reagents, laboratory instruments, and related technologies used to measure extremely small concentrations of hormones, antigens, antibodies, drugs, and other biological substances. RIA is an immunoassay technique that uses radioactively labeled molecules to detect and quantify specific substances in blood, urine, and other biological samples. Its high analytical sensitivity has made it valuable in specialized clinical diagnostics, biomedical research, pharmaceutical development, and endocrinology.
In the United States, RIA has applications in thyroid function assessment, fertility and reproductive hormone testing, insulin measurement, therapeutic drug monitoring, and selected oncology and infectious disease investigations. Although automated chemiluminescent and other nonradioactive immunoassays have replaced RIA in many routine testing applications, the technique continues to serve specialized laboratories and research facilities. The Centers for Disease Control and Prevention (CDC) reports that approximately 14 billion laboratory tests are performed annually across more than 266,000 CLIA-certified laboratories in the United States. This extensive testing infrastructure supports demand for sensitive analytical technologies. However, RIA adoption depends on clinical requirements, laboratory capabilities, radioactive-material handling procedures, and the availability of alternative testing methods.
2026 Estimated New Cancer Cases (Sexes Combined)
- Prostate: 333,830
- Breast: 324,580
- Lung & bronchus: 229,410
- Colorectal: 158,850
- Skin: 119,750
- Melanoma of the skin: 112,000
2026 Estimated Cancer Deaths (Sexes Combined)
- Lung & bronchus: 124,990
- Colorectum: 55,230
- Pancreas: 52,740
- Breast: 42,670
- Prostate: 36,320
- Liver & intrahepatic: 30,980
Growth Drivers of the United States Radioimmunoassay Market
Rising Prevalence of Cancer and Chronic Diseases
The growing burden of cancer, endocrine disorders, and other chronic diseases is an important driver of demand for sensitive laboratory diagnostic techniques in the United States. Radioimmunoassay can measure specific biological markers at low concentrations, making it useful in selected applications involving hormone analysis, biomarker research, and specialized clinical investigations. The National Cancer Institute identifies tumor markers such as thyroglobulin as useful tools for evaluating treatment response and monitoring possible cancer recurrence in appropriate clinical settings. The scale of the U.S. cancer burden further highlights the need for reliable diagnostic and monitoring technologies. According to the CDC’s United States Cancer Statistics program, more than 36.7 million new cancer cases were reported during 2003–2022. Although RIA is not the preferred method for every cancer-related test, its sensitivity supports selected specialized applications and research activities. As healthcare providers increasingly emphasize earlier diagnosis, disease monitoring, and personalized treatment, laboratories may continue using RIA where validated assays offer appropriate analytical performance. This creates opportunities for manufacturers supplying specialized reagents, assay kits, and laboratory equipment.
Expanding Clinical Laboratory Infrastructure and Diagnostic Testing
The extensive clinical laboratory network in the United States supports demand for diagnostic reagents, testing equipment, and specialized analytical methods. Hospitals, independent diagnostic laboratories, academic medical centers, and reference laboratories conduct testing for numerous diseases and physiological conditions. According to the CDC, approximately 14 billion laboratory tests are performed annually in more than 266,000 CLIA-certified laboratories nationwide. This large testing ecosystem creates opportunities for multiple diagnostic technologies, including RIA in applications where its sensitivity and established assay protocols remain useful. RIA reagents and kits are particularly relevant for specialized hormone measurements and research involving low-concentration biological substances. Laboratories may maintain these capabilities to support particular patient populations, research protocols, and tests for which alternative methods are not equally suitable or readily available. Growing emphasis on laboratory accuracy and standardized measurements also encourages investment in dependable testing procedures. The CDC operates standardization programs covering biomarkers associated with thyroid disease, testosterone, estradiol, and other health conditions. These initiatives reinforce the importance of reliable analytical methods, supporting opportunities for assay suppliers while requiring laboratories to demonstrate appropriate accuracy and quality control.
Increasing Pharmaceutical Research and Personalized Medicine
Growth in pharmaceutical research, biotechnology development, and personalized medicine creates additional opportunities for the United States Radioimmunoassay Market. Drug developers and academic researchers require precise analytical techniques to investigate biological pathways, measure hormone concentrations, evaluate drug interactions, and study biomarkers during preclinical and clinical research. RIA can be valuable in specialized research settings because radiolabeled reagents enable the measurement of substances at very low concentrations. The broader diagnostic sector also demonstrates the importance of analytical accuracy. The CDC’s Clinical Standardization Programs focus on improving the reliability and comparability of measurements for biomarkers associated with diabetes, cancer, thyroid disorders, kidney disease, and cardiovascular conditions. These priorities are relevant to laboratories developing and validating sensitive diagnostic methods. Personalized medicine further increases interest in measurements that help researchers understand individual biological responses and treatment outcomes. RIA may contribute to selected biomarker studies, pharmacological investigations, and specialized assay development. However, its adoption depends on the research objective, availability of validated reagents, and comparison with nonradioactive alternatives. Manufacturers that improve assay reproducibility, workflow efficiency, and reagent stability can strengthen their position in research-oriented laboratory markets.
Challenges of the United States Radioimmunoassay Market
Competition from Nonradioactive Diagnostic Technologies
One of the principal challenges facing the U.S. Radioimmunoassay Market is competition from nonradioactive immunoassay technologies. Automated chemiluminescent immunoassays, enzyme-linked immunosorbent assays (ELISA), and other analytical platforms can provide sensitive measurements without requiring radioactive reagents. Many modern systems also offer automated sample processing, faster workflows, and integration with laboratory information systems, making them attractive for hospitals and high-volume diagnostic laboratories. The scale of U.S. laboratory testing creates strong incentives to adopt methods that combine analytical performance with operational efficiency. The CDC reports approximately 14 billion laboratory tests annually across more than 266,000 CLIA-certified laboratories, highlighting the importance of scalable testing infrastructure. In routine clinical settings, laboratories may prefer automated alternatives that simplify sample handling and radioactive-material management. This competitive environment can limit demand for conventional RIA kits, instruments, and consumables. Manufacturers must therefore focus on specialized applications in which RIA offers meaningful analytical advantages or established validation. Improving reproducibility, developing application-specific reagents, and supporting laboratory quality assurance may help suppliers retain customers. Nevertheless, the market’s future depends partly on demonstrating clear value relative to newer diagnostic technologies.
Regulatory Compliance, Radiation Safety, and Operating Costs
Radioimmunoassay requires laboratories to manage radioactive materials responsibly, creating operational and compliance requirements that can restrict adoption. Facilities using radioactive reagents must establish appropriate procedures for storage, handling, contamination prevention, staff training, monitoring, and waste disposal in accordance with applicable federal and state requirements. These activities can increase operational complexity compared with assays that use nonradioactive detection methods. The U.S. Nuclear Regulatory Commission regulates radioactive materials under its jurisdiction, while certain radioactive materials and activities fall under state regulatory programs or other applicable authorities. Requirements depend on the isotope, material, and specific laboratory activity. Laboratories must also follow relevant clinical laboratory quality standards when conducting patient testing. The Food and Drug Administration oversees applicable medical products and diagnostic tests, adding further regulatory considerations for manufacturers developing or marketing covered products. Compliance can require specialized facilities, trained personnel, documentation, quality-control procedures, and appropriate waste-management arrangements. Smaller laboratories may find these costs difficult to justify when alternative technologies are readily available. Consequently, RIA suppliers face pressure to improve safety procedures, reagent handling, and workflow efficiency while maintaining assay accuracy and regulatory compliance.
Radioimmunoassay-Related Product Launches and Developments in the USA
- Access Cortisol – Beckman Coulter (2025): The FDA issued a 510(k)-clearance decision on March 5, 2025, for Access Cortisol on the DxC 500i Clinical Analyzer, supporting cortisol testing in clinical laboratories.
- Elecsys Calcitonin – Roche Diagnostics (2026): The FDA issued a 510(k)-clearance decision on April 24, 2026, for this assay, used to measure calcitonin in clinical testing.
- SPEAR UltraDetect Immunoassays – Spear Bio (2025): Launched on July 25, 2025, this ultrasensitive immunoassay solution initially included four neurological biomarkers: pTau231, pTau217, GFAP, and NfL. It is an alternative immunoassay technology, not a radioimmunoassay.
- cobas c 703 – Roche Diagnostics (2026): FDA-cleared on March 30, 2026, this clinical chemistry analyzer offers throughput of up to 2,000 tests per hour and supports high-volume laboratory workflows.
- cobas ISE neo – Roche Diagnostics (2026): Cleared alongside the cobas c 703, this analytical unit supports electrolyte testing at up to 1,800 tests per hour. It is a laboratory automation development rather than an RIA assay.
- RDi USA Diagnostic Kitting and Fulfillment Services (2026): RDi USA launched at the ADLM Clinical Lab Expo in July 2026, bringing diagnostic kit manufacturing, assembly, logistics, and digital services to U.S. laboratories.
- Estrone RIA Kit – Beckman Coulter (2025): The company issued a recall notice in June 2025 concerning specific Estrone RIA kit lots after a manufacturing-material issue was found. This was a product-quality action, not a new product launch.
- Estrone RIA Kit – Immunotech/Beckman Coulter (2025–2026): FDA records documented further action involving affected Estrone RIA lots, including a recall notice initiated in December 2025 and posted in February 2026.
- Progesterone Coated-Tube RIA Kits – U.S. Federal Research Procurement (2025): A USDA research procurement document specified progesterone coated-tube RIA kits, reflecting continued demand for established RIA products in research laboratories. This was a procurement requirement, not a product launch.
- Estradiol Coated-Tube RIA Kits – U.S. Federal Research Procurement (2025): The same USDA procurement specified estradiol RIA kits for laboratory research, illustrating continued use of radioimmunoassay methods for hormone measurement.
California Research Infrastructure and Biotechnology Innovation
California represents a significant market for radioimmunoassay (RIA) in the United States, supported by its extensive biotechnology industry, academic institutions, and advanced medical research facilities. The state had approximately 39.4 million residents in 2024, creating substantial demand for healthcare services and laboratory diagnostics. Its research ecosystem, including universities, biotechnology companies, and specialized laboratories, supports applications involving hormone measurement, biomarker analysis, and pharmaceutical research. California’s strong life sciences sector encourages collaboration between researchers and diagnostic developers, creating opportunities for specialized RIA kits and reagents. Demand for endocrine testing and clinical research also supports continued use of sensitive analytical methods. However, radioactive-material handling requirements, operational expenses, and competition from automated nonradioactive immunoassays can limit adoption. Investments in laboratory automation, quality assurance, and advanced diagnostic research are helping laboratories improve testing efficiency. Consequently, California’s combination of scientific expertise, healthcare infrastructure, and biotechnology investment supports its continuing importance in the U.S. radioimmunoassay market.
Texas Healthcare Expansion and Medical Research
Texas is an important regional market for radioimmunoassay, supported by its expanding healthcare infrastructure, major medical centers, and growing life sciences research activities. The state’s population reached approximately 31.3 million in July 2024, increasing demand for healthcare services and diagnostic testing. Houston, Dallas, Austin, and San Antonio host hospitals, universities, and research organizations conducting investigations into endocrine disorders, metabolic conditions, and pharmaceutical development. These institutions create potential demand for RIA-based hormone analysis, specialized biomarker testing, and laboratory research. Texas also benefits from collaborations between academic institutions and healthcare providers, encouraging the development of diagnostic capabilities. Nevertheless, radioactive-material management, staff training, equipment maintenance, and regulatory compliance increase operating costs. Competition from automated immunoassays further influences purchasing decisions among laboratories. Continued investment in medical research, laboratory modernization, and specialized diagnostics supports opportunities for RIA suppliers. Texas’s growing healthcare sector and established research centers position it as a meaningful contributor to the U.S. radioimmunoassay market.
New York Advanced Diagnostics and Academic Research
New York maintains an important position in the U.S. radioimmunoassay market because of its concentration of academic medical centers, hospitals, pharmaceutical companies, and biomedical research laboratories. The state had approximately 19.9 million residents in July 2024, supporting demand for clinical testing and specialized healthcare services. New York City and other research hubs host institutions investigating hormone regulation, metabolic disorders, drug interactions, and disease biomarkers. These activities can sustain demand for RIA where highly sensitive measurements are required for clinical or research purposes. Collaboration between universities, healthcare organizations, and biotechnology companies also supports innovation in laboratory testing. However, high operating expenses, radioactive-material handling requirements, and competition from automated nonradioactive diagnostic technologies present challenges. Laboratories must balance analytical performance with testing speed, cost, and safety. Investments in research infrastructure, laboratory quality control, and specialized diagnostic capabilities continue to create opportunities for assay suppliers. New York’s strong medical research ecosystem therefore supports its role in the national radioimmunoassay industry.
Florida Aging Population and Growing Diagnostic Demand
Florida offers growth opportunities for the radioimmunoassay market through its expanding healthcare network, older population, and demand for specialized diagnostic testing. The state had approximately 23.4 million residents in July 2024, creating a substantial healthcare service base. Its hospitals, diagnostic laboratories, universities, and clinical research facilities conduct testing related to endocrine disorders, metabolic conditions, and other health concerns. RIA can support selected applications requiring sensitive measurements of hormones and biological substances, particularly in specialized research and laboratory settings. Florida’s growing medical research activities and healthcare investments provide opportunities for diagnostic suppliers and laboratory service providers. However, adoption is influenced by the costs of radioactive-material handling, waste disposal, staff training, and regulatory compliance. Nonradioactive immunoassays also offer strong competition because of their compatibility with automated clinical laboratory workflows. Investments in laboratory modernization and quality assurance may help specialized facilities maintain reliable testing capabilities. Overall, Florida’s healthcare expansion and clinical research activity support continued demand for sensitive analytical technologies, including RIA in appropriate applications.
Market Segmentations
Product
- Analyzers
- Reagents and Kits
Application
- Research
- Clinical Diagnostics
End User
- Hospitals
- Clinical Diagnostic Laboratories
- Pharmaceutical Industries
- Other
States
- California
- Texas
- New York
- Florida
- Illinois
- Pennsylvania
- Ohio
- Georgia
- New Jersey
- Washington
- North Carolina
- Massachusetts
- Virginia
- Michigan
- Maryland
- Colorado
- Tennessee
- Indiana
- Arizona
- Minnesota
- Wisconsin
- Missouri
- Connecticut
- South Carolina
- Oregon
- Louisiana
- Alabama
- Kentucky
- Rest of United States
All the Key players have been covered
- Overviews
- Key Person
- Recent Developments
- SWOT Analysis
- Revenue Analysis
Company Analysis:
- Danaher (Beckman Coulter, Inc.)
- Berthold Technologies GmbH & Co. KG
- DIAsource ImmunoAssays SA
- BioCheck, Inc. (DRG International Inc.)
- IBL International
- Merck KGaA
- Abbexa
- Institute of Isotopes Co. Ltd.
- Marin Biologic Laboratories, Inc.
- Demeditec Diagnostics GmbH
Report Details:
| Report Features | Details |
| Base Year |
2025 |
| Historical Period |
2022 - 2025 |
| Forecast Period |
2026 - 2034 |
| Market |
US$ Million |
| Segment Covered |
Product, Application, End User and States |
| States Covered |
|
| Companies Covered |
|
| Customization Scope |
20% Free Customization |
| Post-Sale Analyst Support |
1 Year (52 Weeks) |
| Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request) |
Customization Services available
- Analysis of Market Size and Its Segments
- More Company Profiles (Upto 10 without any additional cost):
- Additional Countries (Other than mentioned Countries):
- Region/Country Specific Reports:
- Market Entry Strategy:
- Region-Specific Market Dynamics:
- Regional Market Share Analysis:
- Trade Analysis:
- Production Insights:
- Others Customized Requests:
For more information contact our analysts.
Need More Assistance?
- Talk to our analysts to get more precious information on the current market trends.
- Include more countries and segments and customize the report based on the final requirement.
- Get a competitive advantage in your industry by knowing the report findings and making a positive impact on your revenues and operations.
- Our analysts are always ready to provide more help and pertinent information if you need any additional assistance.
1. Introduction
2. Research & Methodology
2.1 Data Source
2.1.1 Primary Sources
2.1.2 Secondary Sources
2.2 Research Approach
2.2.1 Top-Down Approach
2.2.2 Bottom-Up Approach
2.3 Forecast Projection Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. United States Radioimmunoassay Market
5.1 Historical Market Trends
5.2 Market Forecast
6. Market Share Analysis
6.1 By Product
6.2 By Application
6.3 By End User
6.4 By States
7. Product
7.1 Analyzers
7.1.1 Market Analysis
7.1.2 Market Size & Forecast
7.2 Reagents and Kits
7.2.1 Market Analysis
7.2.2 Market Size & Forecast
8. Application
8.1 Research
8.1.1 Market Analysis
8.1.2 Market Size & Forecast
8.2 Clinical Diagnostics
8.2.1 Market Analysis
8.2.2 Market Size & Forecast
9. End User
9.1 Hospitals
9.1.1 Market Analysis
9.1.2 Market Size & Forecast
9.2 Clinical Diagnostic Laboratories
9.2.1 Market Analysis
9.2.2 Market Size & Forecast
9.3 Pharmaceutical Industries
9.3.1 Market Analysis
9.3.2 Market Size & Forecast
9.4 Other
9.4.1 Market Analysis
9.4.2 Market Size & Forecast
10. Top States
10.1 California
10.1.1 Market Analysis
10.1.2 Market Size & Forecast
10.2 Texas
10.2.1 Market Analysis
10.2.2 Market Size & Forecast
10.3 New York
10.3.1 Market Analysis
10.3.2 Market Size & Forecast
10.4 Florida
10.4.1 Market Analysis
10.4.2 Market Size & Forecast
10.5 Illinois
10.5.1 Market Analysis
10.5.2 Market Size & Forecast
10.6 Pennsylvania
10.6.1 Market Analysis
10.6.2 Market Size & Forecast
10.7 Ohio
10.7.1 Market Analysis
10.7.2 Market Size & Forecast
10.8 Georgia
10.8.1 Market Analysis
10.8.2 Market Size & Forecast
10.9 New Jersey
10.9.1 Market Analysis
10.9.2 Market Size & Forecast
10.10 Washington
10.10.1 Market Analysis
10.10.2 Market Size & Forecast
10.11 North Carolina
10.11.1 Market Analysis
10.11.2 Market Size & Forecast
10.12 Massachusetts
10.12.1 Market Analysis
10.12.2 Market Size & Forecast
10.13 Virginia
10.13.1 Market Analysis
10.13.2 Market Size & Forecast
10.14 Michigan
10.14.1 Market Analysis
10.14.2 Market Size & Forecast
10.15 Maryland
10.15.1 Market Analysis
10.15.2 Market Size & Forecast
10.16 Colorado
10.16.1 Market Analysis
10.16.2 Market Size & Forecast
10.17 Tennessee
10.17.1 Market Analysis
10.17.2 Market Size & Forecast
10.18 Indiana
10.18.1 Market Analysis
10.18.2 Market Size & Forecast
10.19 Arizona
10.19.1 Market Analysis
10.19.2 Market Size & Forecast
10.20 Minnesota
10.20.1 Market Analysis
10.20.2 Market Size & Forecast
10.21 Wisconsin
10.21.1 Market Analysis
10.21.2 Market Size & Forecast
10.22 Missouri
10.22.1 Market Analysis
10.22.2 Market Size & Forecast
10.23 Connecticut
10.23.1 Market Analysis
10.23.2 Market Size & Forecast
10.24 South Carolina
10.24.1 Market Analysis
10.24.2 Market Size & Forecast
10.25 Oregon
10.25.1 Market Analysis
10.25.2 Market Size & Forecast
10.26 Louisiana
10.26.1 Market Analysis
10.26.2 Market Size & Forecast
10.27 Alabama
10.27.1 Market Analysis
10.27.2 Market Size & Forecast
10.28 Kentucky
10.28.1 Market Analysis
10.28.2 Market Size & Forecast
10.29 Rest of United States
10.29.1 Market Analysis
10.29.2 Market Size & Forecast
11. Value Chain Analysis
12. Porter's Five Forces Analysis
12.1 Bargaining Power of Buyers
12.2 Bargaining Power of Suppliers
12.3 Degree of Competition
12.4 Threat of New Entrants
12.5 Threat of Substitutes
13. SWOT Analysis
13.1 Strength
13.2 Weakness
13.3 Opportunity
13.4 Threats
14. Merger and Acquisition
15. Key Players Analysis
15.1 Danaher (Beckman Coulter, Inc.)
15.1.1 Overviews
15.1.2 Key Person
15.1.3 Recent Developments
15.1.4 SWOT Analysis
15.1.5 Revenue Analysis
15.2 Berthold Technologies GmbH & Co. KG
15.2.1 Overviews
15.2.2 Key Person
15.2.3 Recent Developments
15.2.4 SWOT Analysis
15.2.5 Revenue Analysis
15.3 DIAsource ImmunoAssays SA
15.3.1 Overviews
15.3.2 Key Person
15.3.3 Recent Developments
15.3.4 SWOT Analysis
15.3.5 Revenue Analysis
15.4 BioCheck, Inc. (DRG International Inc.)
15.4.1 Overviews
15.4.2 Key Person
15.4.3 Recent Developments
15.4.4 SWOT Analysis
15.4.5 Revenue Analysis
15.5 IBL International
15.5.1 Overviews
15.5.2 Key Person
15.5.3 Recent Developments
15.5.4 SWOT Analysis
15.5.5 Revenue Analysis
15.6 Merck KGaA
15.6.1 Overviews
15.6.2 Key Person
15.6.3 Recent Developments
15.6.4 SWOT Analysis
15.6.5 Revenue Analysis
15.7 Abbexa
15.7.1 Overviews
15.7.2 Key Person
15.7.3 Recent Developments
15.7.4 SWOT Analysis
15.7.5 Revenue Analysis
15.8 Institute of Isotopes Co. Ltd.
15.8.1 Overviews
15.8.2 Key Person
15.8.3 Recent Developments
15.8.4 SWOT Analysis
15.8.5 Revenue Analysis
15.9 Marin Biologic Laboratories, Inc.
15.9.1 Overviews
15.9.2 Key Person
15.9.3 Recent Developments
15.9.4 SWOT Analysis
15.9.5 Revenue Analysis
15.10 Demeditec Diagnostics GmbH
15.10.1 Overviews
15.10.2 Key Person
15.10.3 Recent Developments
15.10.4 SWOT Analysis
15.10.5 Revenue Analysis
Reach out to us
Call us on
USA: +1-478-202-3244
INDIA: +91-120-421-9822
Drop us an email at
info@renub.com